Safety study of FHND1002 granules in healthy adults
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new medication called FHND1002 in healthy adults aged 18 to 45. The goal is to check its safety, how well the body tolerates it, and how it is processed. It is one of the first tests in humans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You are in good general health with no major medical conditions.
- Your body mass index (BMI) is between 19 and 26.
- If you are male, you weigh at least 50 kg (110 lbs); if female, at least 45 kg (99 lbs).
- You agree not to plan a pregnancy and to use effective birth control during the study and for 3 months after.
- You have not taken any prescription or over-the-counter drugs, herbal supplements, or vitamins in the past 14 days (with some exceptions discussed by the study doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (FHND1002) for people with ALS to see if it can slow down the disease. It's for people with ALS who are in the early to moderate stages, have good breathing, and have been recently diagnosed.
This trial studies a new drug called FB418 to see if it's safe and how the body handles it. It first tests single doses in younger healthy men, then multiple doses, and also includes an optional group for healthy older adults.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This trial tests an experimental oral medication called usnoflast for people with ALS. It aims to see if the drug can slow the disease's progression.
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.